2026Sep
LLY Sep 2026 · Sell
Sell. At the $1,149.36 report-date price, the shares stand above $836.00 Fair value and $1,051.71 Potential value.Latest published research · analyzed 2026-09-08 · stale · sources stale
LLY · Archive
Read prior published editions, ratings, and price trends. Each row discloses its own analysis date.
USD 1,149.36
2026May
LLY May 2026 · Strong Buy
Eli Lilly's transformation into a metabolic disease juggernaut is yielding an unprecedented hyper-growth phase. Despite massive near-term capital expenditures compressing free cash flow, the underlying margin expansion and forward earnings trajectory support a significantly higher intrinsic value.Historical archived edition · analyzed 2026-05-08
2026Apr
LLY Apr 2026 · Hold
Eli Lilly (LLY) exhibits explosive top-line hyper-growth, with revenue surging from $34.1B in 2023 to $65.1B in 2025, fueled by its dominant GLP-1 franchise. Despite unparalleled clinical and commercial momentum, the current share price of $851.21 slightly overshoots our intrinsic fair value estimate of $821.95.Historical archived edition · analyzed 2026-04-29